Ligand Pharma (LGND) PT Lowered to $135 at H.C. Wainwright

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/1/2026

1. NVDA
2. PCG
3. AMZN
4. AVGO
5. EIX
6. AAPL
7. SPY
8. STLA
9. PTGX
10. EC

Go back to Ligand Pharma (LGND) PT Lowered to $135 at H.C. Wainwright

OmniAb Business Combination Approved by APAC Shareholders

October 24, 2022 5:00 PM EDT

APAC Shareholder Approval Obtained, Closing Scheduled for November 1, 2022

Ligand Regular Way and Ex-Distribution and OmniAb When-Issued Set to Begin Trading on October 25, 2022

SAN DIEGO--(BUSINESS WIRE)-- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced the business combination (Business Combination) of Avista Public Acquisition Corp. II (APAC) (NASDAQ: AHPA) and OmniAb, Inc. (OmniAb), was approved by APAC shareholders in a vote held this morning, with 96% of the shares represented in person, virtually or by proxy voting in favor of the combination. Based on actual... More

Sermonix Pharmaceuticals Shares Additional Findings From Its ELAINE 1 Clinical Study at the 4th Annual Congress of the International Society of Liquid Biopsy

October 21, 2022 10:00 AM EDT

COLUMBUS, Ohio, Oct. 21, 2022 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat ESR1-mutated metastatic breast and gynecological cancers, today shared additional findings from its Evaluation of Lasofoxifene in ESR1 Mutations (ELAINE 1) Phase 2 study during the 4th Annual Congress of the International Society of Liquid Biopsy (ISLB) in Miami.

Initial results from the open-label (NCT03781063) study assessing the efficacy and safety of Sermonixs lead development candidate, oral lasofoxifene, versus the current standard of care, intramuscular fulvestrant, in postmenopausal women with locally advanced or metastatic ER+/HER2-... More